RUSSELL B. MELCHERT, PHD, RPH

CURRICULUM VITAE

PERSONAL INFORMATION Professional Address: Home Address: University of Missouri-Kansas City (UMKC) 2900 Lewis Drive School of Pharmacy Lee’s Summit, MO 64081 2315 Health Sciences Building (816) 503-6031 2464 Charlotte Street Family: Kansas City, MO 64108-2718 Wife: Stephanie (816) 235-1609; (816) 235-5190 Fax Son: Philip (20) E-mail: Melchertr@umkc.edu Daughter: Sarah (17) CURRENT POSITION 2010-Present: Dean and Professor UMKC School of Pharmacy; Provost: Barbara A. Bichelmeyer, Ph.D. EDUCATION 1990-1994: Ph.D. in Pharmaceutical Sciences (Pharmacology/Toxicology) – May 7, 1994 The University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma 1987-1990: B.S. in Pharmacy – May 12, 1990 The University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma 1985-1987: University Studies/Pre-Pharmacy The University of Oklahoma, Norman, Oklahoma PROFESSIONAL EXPERIENCE 2004-2010: Chair, Department of Pharmaceutical Sciences University of Arkansas for Medical Sciences (UAMS) College of Pharmacy, Dean: Stephanie F. Gardner, Pharm.D., Ed.D. 2008-2010: Professor of Pharmacology (with tenure) UAMS College of Pharmacy, Department of Pharmaceutical Sciences 2004-2010: Associate Professor of Pharmacology and Toxicology UAMS College of Medicine, Department of Pharmacology and Toxicology Department Chair: Nancy J. Rusch, Ph.D. 2001-2008: Associate Professor of Pharmacology (with tenure) UAMS College of Pharmacy, Department of Pharmaceutical Sciences

Melchert; 09/01/16

2

1995-2001: Assistant Professor of Pharmacology UAMS College of Pharmacy, Department of Pharmaceutical Sciences Department Chairs: Allen Bradley, Ph.D. and Charles K. Born, Ph.D. (1995-1998), and Richard H. Kennedy, Ph.D. (1998-2004) 1994-1995: Post-Doctoral Fellow (NIEHS Toxicology Training Grant) The University of Texas at Austin, College of Pharmacy, Department of Pharmacology/Toxicology, Austin, Texas Advisor: Daniel Acosta, Jr., Ph.D. 1990-1994: Graduate Research Assistant The University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma Advisor: Allison A. Welder, Ph.D. 1990-1994: Staff Pharmacist Relief Pharmacists of Oklahoma, Midwest City, Oklahoma Supervisor: Lanada S. Arnold, R.Ph. 1991: Visiting Research Assistant (July – August) Institute of Toxicology, ETH and University of Zurich Schwerzenbach, Switzerland Advisor: Urs A. Boelsterli, Ph.D. 1989: Undergraduate Laboratory Assistant (May – November) The University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma Advisor: Allison A. Welder, Ph.D. 1988-1989: Pharmacy Intern Venture Pharmacy, Midwest City, Oklahoma Preceptor: Lanada S. Arnold, R.Ph. PROFESSIONAL LICENSURE February 1996-Present: Arkansas State Board of Pharmacy, License #08408 August 1990-Present: Oklahoma State Board of Pharmacy, License #11116 FELLOWSHIPS AND SCHOLARSHIPS 2005-2006: American Association of Colleges of Pharmacy Academic Leadership Fellow 1994-1995: NIEHS Toxicology Training Grant Post-Doctoral Trainee The University of Texas at Austin 1993-1994: American Foundation for Pharmaceutical Education/Sterling Winthrop Industry-Oriented Pre-Doctoral Fellowship 1991-1993: American Foundation for Pharmaceutical Education Pre-Doctoral Fellowship 1993: John B. Bruce Scholarship for the Outstanding Graduate Student in Medicinal Chemistry and Pharmacodynamics at The University of Oklahoma 1990-1992: The University of Oklahoma Provost's Pre-Doctoral Graduate Assistantship 1985-1986: University Scholar, The University of Oklahoma, Norman, Oklahoma

Melchert; 09/01/16

3

AWARDS AND HONORS 2016: UMKC Pharm.D. Class of 2018 Teacher of the Year 2016: UMKC Graduate Student Council Outstanding Interdisciplinary Faculty Award 2016: American Board of Wound Management Board of Directors 2015: UMKC Pharm.D. Class of 2017 Teacher of the Year Runner Up 2015: Phi Lambda Sigma, Beta Eta Chapter Alumnus of the Year 2014: Honorary President, Missouri Pharmacy Association 2014: UMKC Pharm.D. Class of 2016 Teacher of the Year 2013: Visiting Nurse Association Board of Directors 2013: UMKC Pharm.D. Class of 2015 Teacher of the Year 2012: UMKC Student Government Association Apple Polisher’s Award 2012: UMKC Pharm.D. Class of 2014 Teacher of the Year 2010: UAMS College of Pharmacy Teacher of the Year (Selected by Entire Student Body) 2010: Student National Pharmaceutical Association Faculty/Teacher of the Year 2010: Selected by the Class of 2010 to give the Faculty Address at the Honors Convocation 2010: UAMS College of Pharmacy, Class of 2010 Most Outstanding Professor in the Department of Pharmaceutical Sciences 2008: Selected by the Class of 2008 to give the Faculty Address at the Honors Convocation 2008: Chairman, American Heart Association Pulaski County Board of Directors 2007: Selected by the Class of 2007 to give the Faculty Address at the Honors Convocation 2006: President, American Heart Association Pulaski County Board of Directors 2006: UAMS College of Pharmacy Teacher of the Year (Selected by Entire Student Body) 2006: Selected by the Class of 2006 to give the Faculty Address at the Honors Convocation 2006: UAMS College of Pharmacy, Class of 2006 Most Outstanding Professor in the Department of Pharmaceutical Sciences 2006: Student National Pharmaceutical Association Faculty Member of the Year 2005: President-Elect, American Heart Association Pulaski County Board of Directors 2004: Member of the Cardiology Study Section of the Veterans Affairs Merit Review 2003: Selected by the Class of 2003 to give the Faculty Address at the Honors Convocation 2002: American Heart Association Little Rock Division Board of Directors 2002: UAMS College of Pharmacy Teacher of the Year (Selected by Entire Student Body) 2002: UAMS College of Pharmacy, Class of 2002 Most Outstanding Professor in the Department of Pharmaceutical Sciences 2001: Selected by the Class of 2001 to give the Faculty Address at the Honors Convocation 1999: UAMS College of Pharmacy Teacher of the Year (Selected by Entire Student Body) 1999: UAMS College of Pharmacy, Class of 2001 Teacher of the Year 1998: UAMS College of Pharmacy, Class of 1998 Most Outstanding Professor in the Department of Biopharmaceutical Sciences 1997: UAMS College of Pharmacy, Kappa Psi Teacher of the Year 1994: Sigma Xi Award for Basic Research, 1994 OUHSC Graduate Education Research Day 1994: Nominated for 1994 OUHSC Outstanding Doctoral Dissertation Award 1994: Alpha Epsilon Lamda (Graduate Student Honor Society) 1993: Phi Delta Chi Pharmaceutical Fraternity Outstanding Alumnus (Rho Chapter, OUHSC) 1993: Student Travel Award for the 1993 Annual Meetings of the Society of Toxicology 1991: Hope E. Hopps Student Travel Award, 1991 World Congress on Cell and Tissue Culture 1991: Student Travel Award for the 1991 Annual Meetings of the Society of Toxicology

Melchert; 09/01/16

4

1990: Merck, Sharp, and Dohme Award for Outstanding Academic Achievement in Pharmacodynamics and Toxicology 1988: Rho Chi Society (Pharmaceutical Honor Society) 1985: Salutatorian, Liberal High School, Liberal, Kansas (Graduated 2nd in Class of 162) INSTRUCTION: UMKC DOCTOR OF PHARMACY CORE CURRICULUM 2015-Present: Pharmacology II (Pharm 7362). Lipid Lowering Agents, Antihypertensive Drugs, Vasodilators & Anti-Anginal Drugs, Drugs for Heart Failure, Antiarrhythmic Drugs. 22 Contact Hours. 2012-2014: Pharmacology II (Pharm 7362). Lipid Lowering Agents, Antihypertensive Drugs, Vasodilators & Anti-Anginal Drugs, Drugs for Heart Failure. 19 Contact Hours. INSTRUCTION: UMKC DOCTOR OF DENTAL SURGERY CORE CURRICULUM 2016-Present: Introduction to Pharmacology (Dent 6564). Introduction to Pharmacology, How Drugs Act: Molecular & Cellular Aspects. 4 Contact Hours. INSTRUCTION: UMKC SCHOOL OF GRADUATE STUDIES (GRADUATE STUDENT COMMITTEES) 2015-2016: Ph.D. Committee Member for Byeongtaek Oh. Dissertation: Development and evaluation of nanocarriers against atherosclerosis. 2015-2016: Ph.D. Committee Member for Animkh Ray. Dissertation: Novel approaches for targeted delivery of cancer therapeutics to nuclei of malignant cells. 2015-2016: Ph.D. Committee Member for Sujay Shah. Dissertation: Novel folic acid targeted nanomicelles for delivery of hydrophobic drugs tot eh back of the eye. 2014-2015: Ph.D. Committee Member for Anusha Ande. Dissertation: Cytochrome P450 enzymes and oxidative stress in tobacco/nicotine mediated HIV pathogenesis. 2014-2015: Ph.D. Committee Member for Ravi D. Vaishya. Dissertation: Effect of nanomicelle size on trans-scleral permeability of dexamethasone and strategies to minimize octreotide acylation during sustained release from biodegradable polymers. 2011-2013: Ph.D. Committee Member for Ankit Shah. Dissertation: HIV-1 gp120 and methamphetamine-mediated induction of proinflammatory cytokines/chemokines and oxidative stress in astrocytes: implications in neuroinflammation. INSTRUCTION: UAMS DOCTOR OF PHARMACY CORE CURRICULUM 2007-2010: Course Coordinator for Pharmacology II (PhSci 4134). Antibacterial, Antifungal, and Antiviral Agents. 35 Contact Hours. 2007-2010: Pharmacology I (PhSci 4124). Anabolic-Androgenic Steroids, Histamine and Antihistamines, Non-Steroidal Antiinflammatory Drugs, Drugs Used to Treat Asthma, Drugs for Gastrointestinal Ulcer, Drugs for Gastrointestinal Hyper- or Hypo-Motility. 14 Contact Hours. 2004-2010: Pharmaceutical Biotechnology (PhSci 5623). Gene Therapy, Pharmacogenomics, Antisense Oligonucleotides, Therapeutic Antibodies. 9 Contact Hours. 2003-2007: Course Coordinator for Pharmacology II (PhSci 4134). Cardiovascular Drugs, Antibacterial, Antifungal, and Antiviral Agents. 50 Contact Hours.

Melchert; 09/01/16

5

2003-2007: Pharmacology I (PhSci 4124). Anabolic-Androgenic Steroids, Histamine and Antihistamines, Non-Steroidal Antiinflammatory Drugs, Drugs Used to Treat Asthma, Drugs for Gastrointestinal Ulcer, Drugs for Gastrointestinal Hyper- or Hypo-Motility, Cardiovascular Drugs. 27 Contact Hours. 1997-2003: Course Coordinator for Pharmacology III (PhSci 4134). Antibacterial, Antifungal, and Antiviral Agents. 35 Contact Hours. 1996-2002: Pharmacology II (PhSci 4124). Anabolic-Androgenic Steroids, Histamine and Antihistamines, Non-Steroidal Antiinflammatory Drugs, Drugs Used to Treat Asthma, Drugs for Gastrointestinal Ulcer, Drugs for Gastrointestinal Hyper- or Hypo-Motility. 16 Contact Hours. 2002-2003: Current Topics in Pharmacy Practice (PhPr 5692). Pharmacogenomics. 3 Contact Hours. 2000-2002: Pharmaceutical Biochemistry (PhSci 3214). Biotechnology. 4 Contact Hours. 1996: Pharmacology III (PhSci 4134). Antibacterial, Antifungal, and Antiviral Agents. 35 Contact Hours. 1995: Pharmacology II (PhSci 4124). Anabolic-Androgenic Steroids, Histamine and Antihistamines, Non-Steroidal Antiinflammatory Drugs, Anti-Parkinson’s Drugs. 8 Contact Hours. INSTRUCTION: UAMS DOCTOR OF MEDICINE CORE CURRICULUM 2004-2010: Medical Pharmacology. General Principals of Antimicrobial Therapy, Penicillins and Cephalosporins, Protein Synthesis Inhibitors; DNA Synthesis Inhibitors; Drugs for Gastroinestinal Tract Infections; Drugs for Respiratory Tract Infections. 7 Contact Hours. 2004-2009: USMLE Step 1 Review Session on Pharmacology. Anti-Infective Agents. 1.5 Contact Hours. 2002-2004: Medical Pharmacology. General Principals of Antimicrobial Therapy, Penicillins and Cephalosporins. 2 Contact Hours. INSTRUCTION: UAMS GRADUATE SCHOOL (DIDACTIC TEACHING) 2009-2010: Experimental Pharmacology & Toxicology (PCOL 5203). Biotelemetry. 1.5 Contact Hours. (Course taught every year). 2000-2010: Toxicology for Graduate Students (INTX 5063). Cardiovascular Toxicology. 3 Contact Hours. (Course taught every year). 1997-2003: Methods in Pharmaceutical Sciences (PHSC 5053). Care and Use of Laboratory Animals, General Laboratory Safety, Cell Culture Techniques. 6 Contact Hours. Served as Course Coordinator for 1997-1998. (Course taught on demand). 1998-1999: Course Coordinator for Seminar in Pharmaceutical Sciences (PHSC 5041) INSTRUCTION: UAMS GRADUATE SCHOOL (GRADUATE STUDENTS DIRECTED) 2000-2002: Major Advisor for Nathan Petty, M.S. Thesis: Sodium/Hydrogen Exchange Inhibitors for the Resuscitation of Hemorrhagic Shock 1998-2000: Major Advisor for Hui Liu, M.S. Thesis: Lovastatin Inhibits Phenylephrine- Induced ERK Activation and Growth of Cardiac Myocytes 1996-1998: Major Advisor for Hong Wang, M.S. Thesis: Androgen-Induced Cardiomyocyte Hypertrophy

Melchert; 09/01/16

6

INSTRUCTION: UAMS GRADUATE SCHOOL (GRADUATE STUDENT COMMITTEES) 2009-2010: Ph.D. Committee Member for Shubhra Chaudhuri. Dissertation: Mechanism of HIF 1 Alpha Induction in Acetaminophen-Mediated Hepatotoxicity. 2008-2009: Ph.D. Committee Member for Swapnil Sonkusare. Dissertation: Upregulation of Vascular L-Type Calcium Channels in Hypertension: Role of b Subunits. 2005-2007: Ph.D. Committee Member for Brian Donahower. Dissertation: Examination of Vascular Endothelial Growth Factor (VEGF) in a Mouse Model of Acetaminophen Toxicity. 2005-2007: Ph.D. Committee Member for Rajesh Vadlapatla. Dissertation: Drug-Organic Electrolyte Complexes as Controlled Release Systems. 2005-2007: Ph.D. Committee Member for Zabeena Shaik. Dissertation: Role of Protein kinase B/Akt in S-(1, 2-dichlorovinyl)-L-cysteine induced mitochondrial dysfunction and cell death in renal proximal tubular cells. 2003-2006: Ph.D. Committee Member for Meagan B. Myers. Dissertation: Depletion of Mitochondrial DNA After In Utero Exposure to AZT and AZT-Containing Anti-Retroviral Therapies 2001-2005: Ph.D. Committee Member for Beth Maris. Dissertation: Gender Differences in Cardiac Remodeling in Spontaneously Hypertensive and WKY Normotensive Rats. 2001-2003: Ph.D. Committee Member for Yun Ge. Dissertation: Neonatal Ethanol-Induced Purkinje Cell Loss: Possible Mechanisms and Approaches for Detection 2001-2002: Ph.D. Committee Member for James X. Yu. Dissertation: Cellular Mechanisms and Signal Transduction Pathways Underlying Interleukin-6-Induced Negative Inotropic Effect in Adult Ventricular Myocytes 2000-2002: Ph.D. Committee Member for Dian Cao. Dissertation: Aging and Cardiac Function 2001-2003: M.S. Committee Member for Kristina L. Lovin, M.S. Thesis: Predicting Pharmacokinetic Herb/Drug Interactions via Cytochrome P450 Phenotyping (Citrus aurantium and Echinacea purpurea) 1999-2001: M.S. Committee Member for Jiaxuan Zhou. Thesis: Tumor Necrosis Factor-a Induced Apoptosis of Cardiac Myocytes 1997-1999: M.S. Committee Member for Donna Jenkins. Thesis: Neonatal Ethanol-Induced Alterations of Neurotrophin Receptor Expression in the Rat Cerebellum 1997-1999: M.S. Committee Member for Yun Ge. Thesis: Neonatal Ethanol-Induced Alterations of Neurotrophin Receptor mRNA in Rat Cerebellum 1995-1996: M.S. Committee Member for Nassar Nyamweya, M.S. Thesis: Cocaine Pharmacokinetics in Neonatal Rats 1995-1996: M.S. Committee Member for Haijuan Yang, M.S. Thesis: Comparative Pharmacokinetics of Methadone in Neonatal Rats Following Intragastric Intubation Using Various Nutrient Vehicles INSTRUCTION: UNDERGRADUATE RESEARCH EXPERIENCES 2008: Faculty Advisor for Sidalay Chanthaseny, Pharm.D. Student in the UAMS College of Pharmacy A. Nelson Voldeng Summer Research Fellowship 2006: Faculty Advisor for Justin Adams, Pharm.D. Student in the UAMS/Arkansas Cancer Research Center’s Partners in Research Program 2005: Faculty Advisor for Katrina Harp, Pharm.D. Student in the UAMS/Arkansas Cancer Research Center’s Partners in Research Program

Melchert; 09/01/16

7

2002: Faculty Advisor for Jennifer Rossi, Pharm.D. Student in the UAMS College of Pharmacy A. Nelson Voldeng Summer Research Fellowship 2001: Faculty Advisor for John Vinson, Pharm.D. Student in the UAMS College of Pharmacy A. Nelson Voldeng Summer Research Fellowship 1996: Faculty Advisor for Antionetta Harden, Undergraduate Student at the University of Arkansas at Little Rock McNair Scholars Program SERVICE: UMKC DEAN RESPONSIBILITIES & ACCOMPLISHMENTS 2010-Present: Academic and administrative leadership for the School of Pharmacy consisting of ~60 full-time faculty, ~40 full-time staff, and ~530 pharmacy students and ~50 doctoral graduate students 2010-Present: Fiscal responsibility and leadership for approximately $16,000,000 in state and tuition revenue and ~$2,400,000 in extramural grants and contracts 2010-Present: Represent the School in the campus, university system, community, state, and nation 2010-Present: Net Fundraising Productivity (including planned giving): $2,495,860 (FY11); $277,952 (FY12); $2,213,502 (FY13); $1,816,606 (FY14); $197,749 (FY15) 2016-2017: Developed and implemented additional evaluation standards for annual faculty and staff assessment of professional and ethical behavior 2015-2016: Facilitated and secured the recruitment of 7 new faculty in the Division of Pharmacy Practice and Administration (Lost 3 Faculty and 1 retired in DPPA) 2014-2016: Oversight of comprehensive self-study for accreditation renewal 2015-2016 2014-2015: Facilitated and secured the recruitment of 3 new faculty in the Division of Pharmacy Practice and Administration (Lost 6 Faculty in DPPA) 2012-2014: Oversight of focused self-study for expansion of program to Springfield, MO 2011-2016: Advocated for and secured $2,000,000 per year from the State of Missouri to expand the UMKC PharmD program to the Missouri State University campus in Springfield 2013-2014: Recruited 2 new regional Associate Deans to lead distant sites 2013-2014: Facilitated and secured the recruitment of 2 new faculty in the Division of Pharmacy Practice and Administration (Lost 2 Faculty in DPPA) 2010-2014: Directed revision of the Strategic Plan including establishment of the Core Values statement 2012-2013: Facilitated and secured the recruitment of 2 new faculty in the Division of Pharmacy Practice and Administration (Lost 2 Faculty in DPPA) 2011-2012: Facilitated and secured the recruitment of 2 new faculty in the Division of Pharmacy Practice and Administration (Lost 2 Faculty in DPPA) 2010-2011: Facilitated and secured the recruitment of 3 new faculty in the Division of Pharmacy Practice and Administration (Lost 1 Faculty in DPPA) 2010-2011: Charged Associate Dean for Student Affairs and Admissions Committee to implement PharmCAS and revise admissions procedure to whole file review 2010-2011: Reconfigured leadership team of the School to include two Associate Dean positions (Student Affairs and Academic Affairs)

Melchert; 09/01/16

8

SERVICE: UMKC CAMPUS-WIDE COMMITTEES 2016-Present: School of Medicine LCME Executive Committee (Comprehensive Self Study) 2015-Present: Research Advisory Council 2014-Present: Member, University Budget Committee (UMKC is an RCM model) 2011-Present: Interprofessional Education Steering Committee (Chair, 2013-2015) 2011-Present: Frontiers Heartland Institute for Clinical and Translational Research Deans’ Advisory Council 2010-Present: Dean’s Council 2010-Present: Administrative Council 2010-Present: Health Sciences Deans’ Council 2016: Member, UMKC Graduate Student Assistantships Task Force 2015: Member, UMKC Provost Search Committee 2014: Member, School of Medicine Dean Search Committee 2013-2014: Bloch School of Management “Time for Excellence: Transforming the Bloch School” Implementation Team 2012-2013: Chair, School of Nursing and Health Studies Dean Search Committee 2011: Member, Search Committee for the Dean of Graduate Studies and Vice-Provost for Faculty Affairs 2011: School of Medicine Advisory Committee 2010-2014: Deans for Research Committee 2010-2014: Life and Health Sciences Advisory Committee SERVICE: UAMS DEPARTMENT CHAIR RESPONSIBILITIES & ACCOMPLISHMENTS 2004-2010: Increased Department faculty members from 16 to 21 including loss of four faculty members (one to death, two transfers, one promotion/tenure denial) and recruitment and hiring of eight new faculty members. 2004-2010: Increased Department research resources including: ~$735,000 in equipment start- up funds, ~$750,000 in laboratory renovations), ~$300,000 in equipment grant funds, and ~ $170,000/year bridge/pilot funding for faculty 2004-2010: Department extramural research direct funding reached ~$1,446,353 in 2008-2009 2004-2010: Conducted annual reviews of faculty and staff performance including assessment of teaching effectiveness, research progress, and service accomplishments for department faculty members and administrative staff members. 2004-2010: Prepared Department Annual Report delineating faculty teaching effort, extramural revenue from grants and contracts, publications, service effort, and accountability for Department expenditures. 2004-2010: Prepared annual department budget including faculty and staff salary (~$1,800,000/yr). Maintained departmental accounts and directed departmental spending including a departmental maintenance account ($66,300/yr), departmental incentive account (~$20,000/yr), and teaching account (~$9,000/yr). 2004-2010: Served on the College of Pharmacy Executive Committee and made recommendations to the Dean on College policies and procedures. 2008-2010: Developed new Division of Radiation Health within the Department and recruited the Director and subsequently five additional faculty members. 2005-2010: UAMS College of Pharmacy Development Committee 2006-2010: Member of the Dean’s Society, UAMS College of Pharmacy

Melchert; 09/01/16

9

2008-2009: UAMS Chancellor’s Cabinet Strategic Planning Retreat; Member of the UAMS Outreach Planning Group. 2007-2008: Drafted and directed the development of the Mission Statement for the Department of Pharmaceutical Sciences. 2006-2008: Drafted and directed revisions in the basic science courses for the Pharm.D. Curriculum including deletion of seven credit hours and creation of five new credit hours of basic science courses. 2006-2007: Proposed, budgeted and directed Pharmaceutical Sciences laboratory renovations. Phase II (1,600 sq. ft) completed in fall 2007 ($570,000). 2006-2007: Chaired ACPE Self Study Committee on Standards for Organization and Administration. 2007: Department of Pharmaceutical Sciences ranked fifth in the nation according to the Faculty Scholarly Productivity Index published by Academic Analytics. The survey ranked 104 disciplines at 354 institutions including over 17,000 faculty, and evaluated publications, citations, and grants for 2003-2005. The Chronicle of Higher Education, January 12, 2007. 2005-2006: Proposed, budgeted, and directed Pharmaceutical Sciences laboratory renovations. Phase I (700 sq. ft.) completed in fall 2006 ($170,000). 2004-2007: Recruited faculty for four new positions. Three where filled by 2006, one in 2008. Secured start-up funding of approximately $485,000 total for those three new faculty recruits for research instrumentation and technician salary support. SERVICE: UAMS CAMPUS-WIDE COMMITTEES 2009-2010: Adult Genetics Subcommittee of the Arkansas Genetics Health Advisory Committee 2007-2010: College of Nursing Tailored Biobehavioral Interventions Research Center Advisory Committee 2007-2010: Teaching with Technology Committee 1996-2010: Biomedical Research Building Facilities Management Committee 2008-2009: UAMS Chancellor’s Cabinet Strategic Planning Outreach Subcommittee 2007-2008: Chief of Genetics Search Committee 2007: UAMS Campus Promotion & Tenure Appeal Committee 2003-2005: Graduate Council, Pharmaceutical Sciences Representative 2001-2005: Committee on Assessment, Graduate Council; Served as Chair 2004 2004: Graduate School Dean Search Committee 2002-2003: Pharmacy Dean Search Committee 1997-2001: Committee on Faculty, Graduate Council 1996-2000: Academic Services Advisory Committee; Served as Chair 1996-1997 1997-1999: Committee for Allocation of Graduate Student Research Funds 1996: Office of Educational Development, Evaluator Search Committee SERVICE: UAMS COLLEGE OF PHARMACY COMMITTEES 2004-2010: Executive Committee 2007-2010: Assessment Committee (also served 2000-2002), Served as Chair 2009-2010 2009-2010: Continuing Professional Development Ad-Hoc Committee 2008-2010: Summative Exam 1 Subcommittee of the Assessment Committee

Melchert; 09/01/16

10

2004-2008: Scholastic Standing Committee 2004-2007: Awards and Financial Aid Committee (also served 1996-1999) 2002-2004: Admissions Committee (also served 1997-1999) 2001-2004: Promotion and Tenure Committee 2000-2004: Chair, Pharmacy Student Research Committee 1996-2004: Voldeng Fellowship Selection Committee 2000-2002: Student-Faculty Affairs Committee (also served 1996-1997) 1999: Department of Pharmaceutical Sciences Faculty Search Committee 1996-1999: Graduate Committee 1996-1999: Pharmaceutical Sciences Seminar Committee; Served as Chair 1998-1999 1996-1997: Joint Pharm.D./Ph.D. Study Committee SERVICE: MEMBERSHIP/SERVICE IN PROFESSIONAL AND SCIENTIFIC ORGANIZATIONS American Association of Colleges of Pharmacy – Member since 1995 Representative to the COD Administrative Board (Elected Nationally) 2015-2017 Research and Graduate Affairs Committee 2016-2017 Dean Facilitator for Academic Leadership Fellows Program 2015-2016 UMKC Administrative Delegate to AACP from 2010-Present Council of Deans Resolutions Committee 2014-2015 Center for the Advancement of Pharmacy Education Advisory Panel 2012-2013 Volwiler Research Achievement Award Selection Committee 2012-2013 Council of Deans Task Force on Pharmacy Support Personnel 2011-2012 Academic Affairs Committee 2010-2011 Task Force on Work Force 2009-2010 Task Force on Pharmaceutical Sciences and Research Education 2008-2009 Academic Leadership Fellows Program 2005-2006 UAMS Faculty Delegate to AACP from 2000-2001 American Pharmacists Association – Member Since 1990 Member, APhA House of Delegates, Missouri Delegate 2011 Member, APhA House of Delegates, Missouri Delegate 2012 Member, APhA House of Delegates, Missouri Delegate 2015 American Society of Health Systems Pharmacists – Member Since 2010 Missouri Pharmacy Association – Member Since 2010 Ex Officio Member of the Board of Directors 2012-Present Member of the Professional Affairs Committee 2012-2013 Arkansas Pharmacists Association – Member Since 2004 Kansas Pharmacists Association – Member Since 2011 Missouri Society of Health Systems Pharmacists – Member Since 2010 American Heart Association – Member 1998-2010 Chairman of the Board of Directors of the Pulaski County Division 2008-2009 President of the Board of Directors of the Pulaski County Division 2006-2008 President-Elect of the Board of Directors of the Pulaski County Division 2005-2006 Member of the Heartland Affiliate Research Committee from 2001-2004 Member of the Board of Directors of the Pulaski County Division 2002-2010 Society of Toxicology – Student Member 1990-1996; Member 1996-2010; Member of the Committee on Public Communications: 2000-2003

Melchert; 09/01/16

11

Chair of the Committee on Public Communications: 2002-2003 Chaired the Cardiovascular Poster Session at the 2001 Annual Meeting American Board of Wound Management Board of Directors – Member Since 2016 Visiting Nurse Association Kansas City Board of Directors – Member Since 2013 SERVICE: ACCREDITATION COUNCIL FOR PHARMACY EDUCATION 2016: Site Visit Team Member for the University of Tennessee Health Sciences Center 2016: Reviewer for Accreditation Application for State University of New York-Binghamton 2016: Site Visit Team Member for Concordia University 2013: Site Visit Team Member for the University of Utah 2013: Site Visit Team Member for Marshall University 2012: ACPE Evaluator Workshop October 4-5, 2012 SERVICE: EXTERNAL REVIEWER FOR SCIENTIFIC JOURNALS 1997-Present: Editorial Board, Toxicology In Vitro, Editor: Daniel Acosta, Jr., Ph.D. 2002-Present: Editorial Board, Cardiovascular Toxicology, Editor: Y. James Kang, DVM, Ph.D. 2012-Present: Editorial Board, Regenerative Medicine Research, Editor-in-Chief: Y. James Kang, DVM, Ph.D. 1996-2010: Toxicology Letters, Editor: James P. Kehrer, Ph.D. 2001-2010: Toxicology and Applied Pharmacology, Editor: Michael P. Waalkes, Ph.D. 2003: Toxicogenomics, Editor: Ken Ramos, Ph.D. 2003: Experimental Biology and Medicine, Editor: Dale R. Romsos, Ph.D. 2001: British Journal of Sports Medicine, Editor: Paul McCrory, Ph.D. 1999: Biochemical Pharmacology, Editor: Alan C. Sartorelli, Ph.D. 1998: Neurological Research, Editor: Manuel Dujovny, M.D. 1997: Drug and Alcohol Dependence, Editor: Chris-Ellyn Johanson, Ph.D. 1996: Nutrition Research, Editor: Ranjit Kumar Chandra, M.D. SERVICE: EXTERNAL REVIEWER FOR GRANT APPLICATIONS 2010-2016: Annual Meeting Abstract Reviewer for Biological Sciences Section of the American Association of Colleges of Pharmacy 2009-2011: Reviewer for the American Association of Colleges of Pharmacy New Investigator Award 2002-2008: Reviewer for the Veterans Affairs Merit Review, Cardiology Study Section 2004: Reviewer for the UAMS Medical Research Endowment Awards 2003: Ad-hoc Reviewer for the Kentucky Science and Engineering Foundation 2002-2003: Ad-hoc Reviewer for the Philip Morris External Research Program MEDIA COMMENTARY/INTERVIEWS 1.   KTHV Little Rock CBS Affiliate: Comment on Adverse Effects of Anabolic-Androgenic

Steroids. Interviewed by Sports Reporter Mark Edwards for the television news story: Girls Taking Steroids for Body Shaping. April 29, 2005.

2.   KTHV Little Rock CBS Affiliate: Comment on Adverse Effects of Anabolic-Androgenic Steroids. Interviewed by Sports Reporter Mark Edwards for the television news story: Bonds Smashes Homerun #756. August 8, 2007.

Melchert; 09/01/16

12

3.   KATV Little Rock ABC Affiliate: Promotion of the American Heart Association Festival of the Wines fundraising event. August 18, 2008.

4.   KCUR Kansas City Public Media, Part of the NPR Digital Network: Black Market Steroids Abound, Attract Fewer Teens. Radio Interview. April 20, 2012.

5.   KCPT Kansas City PBS Affiliate: Missouri measure would enable “right to try” drug program for dying patients: critics argue legislation is redundant, misguided. June 20, 2014.

6.   Scope of Practice: Pharmacists are providing more patient care services than ever, but their scope of practice still has room to grow. Elements. 5(2):6-7, 2016.

INVITED PRESENTATIONS 1.   The University of Oklahoma Health Sciences Center College of Pharmacy, Continuing

Education Program, Oklahoma City, Tulsa, Enid, and Ardmore, Oklahoma. Sponsor: Robert Holt, R.Ph. Adverse Effects of Anabolic-Androgenic Steroid Abuse. Spring 1994.

2.   UAMS College of Pharmacy, Department of Biopharmaceutical Sciences, Little Rock, Arkansas. Sponsor: Cesar M. Compadre, Ph.D. Non-Sedating Antihistamine-Induced Cardiotoxicity In Vitro. September 19, 1995.

3.   Ligand Pharmaceuticals, Department of Endocrine Research, San Diego, California. Sponsor: William T. Schrader, Ph.D. Toxicity of Androgenic Agonists and Antagonists. April 17, 1998.

4.   UAMS College of Pharmacy, Continuing Education Program, Little Rock, Arkansas. Sponsor: Jack McCormack, Ph.D. Bacterial Infectious Diseases and Resistance. 1 Contact Hour. September 20, 1998.

5.   UAMS College of Pharmacy, Continuing Education Program, Little Rock, Arkansas. Sponsor: Jack McCormack, Ph.D. New Antibiotics. 1 Contact Hour. September 20, 1998.

6.   University of Arkansas at Little Rock, Men’s Health Week, Little Rock, Arkansas. Sponsor: Bobby Pitts, R.N.P. Creatine as an Ergogenic Aid. April 15, 1999.

7.   UAMS College of Medicine, Department of Pharmacology and Toxicology, Little Rock, Arkansas. Sponsor: Scott M. Belcher, Ph.D. Signaling Pathways of Cardiac Hypertrophy. October 20, 1999.

8.   UAMS College of Pharmacy, Department of Pharmaceutical Sciences, Little Rock, Arkansas. Sponsor: Shi Jesse Liu, Ph.D. Fluorescent Measurement of Cardiac Calcium Transients. January 21, 2000.

9.   UAMS College of Pharmacy, Continuing Education Program, El Dorado, Arkansas. Sponsor: H.C. Gardner, III, Pharm.D. Anabolic-Androgenic Steroid Abuse and Other Ergogenic Aids. 2 Contact Hours. February 6, 2000.

10.   UAMS College of Pharmacy, Continuing Education Program, Fayetteville, Arkansas. Sponsor: H.C. Gardner, III, Pharm.D. Cardiovascular Benefits of Statins: More Than Just the Lipids? 1 Contact Hour. September 24, 2000.

11.   UAMS College of Pharmacy, Continuing Education Program, Helena, Arkansas. Sponsor: H.C. Gardner, III, Pharm.D. Cardiovascular Benefits of Statins: More Than Just the Lipids? 1 Contact Hour. November 5, 2000.

12.   Experimental Biology 2002 Annual Meeting, New Orleans, Louisiana. Sponsor: Y. James Kang, DVM, Ph.D. Myocardial Cell Signaling Pathways. April 21, 2002.

13.   American Heart Association Texarkana Division Board of Directors meeting. Sponsor: Kim Langdon, President. Cellular Cardiomyoplasty: Treatment for MI in the 21st Century? May 9, 2002.

Melchert; 09/01/16

13

14.   American Heart Association Little Rock Division Board of Directors meeting. Sponsor: Missy Lewis, Metro Executive Director. Cellular Cardiomyoplasty: Treatment for MI in the 21st Century? September 17, 2002.

15.   South University School of Pharmacy. Sponsor: James K. Porter, Ph.D. Altering Cardiac/Cardiomyocyte Function with Drugs, Hormones, and Implanted Cells. May 7, 2003.

16.   UAMS College of Pharmacy, Department of Pharmaceutical Sciences, Little Rock, Arkansas. Sponsor: Philip Breen, Ph.D. Experimental Interventions in Cardiac Remodeling. October 1, 2004.

17.   Arkansas State University, Department of Chemistry, Jonesboro, Arkansas. Sponsor: Michael Panigot, Ph.D. Experimental Interventions in Cardiac Remodeling. October 5, 2004.

18.   UAMS College of Medicine, Department of Pharmacology and Toxicology, Little Rock, Arkansas. Sponsor: John Crow, Ph.D. Experimental Interventions in Cardiac Remodeling. January 19, 2005.

19.   Arkansas Children’s Hospital, UAMS Department of Pediatrics Grand Rounds, Little Rock, Arkansas. Sponsor: Laura James, M.D. Cardiovascular Effects of Anabolic-Androgenic Steroids. February 21, 2006.

20.   UAMS College of Pharmacy, Department of Pharmaceutical Sciences, Little Rock, Arkansas. Sponsor: Cesar M. Compadre, Ph.D. Is Professionalism in Pharmacy Education Addressed from a “Four-Frame” Point of View?. January 25, 2008.

21.   Universidad Tecnica Particular de Loja, Loja, Ecuador. Sponsor: Omar Malagon Aviles, Ph.D. Basic Science Education in the PharmD Program at UAMS. January 27, 2009.

22.   Universidad Tecnica Particular de Loja, Loja, Ecuador. Sponsor: Omar Malagon Aviles, Ph.D. Basic Pharmaceutical Sciences Research at UAMS. January 27, 2009.

23.   UAMS College of Pharmacy, Faculty Retreat, Little Rock, Arkansas. Sponsor: Stephanie Gardner, Pharm.D., Ed.D. Promotion and Tenure in the College of Pharmacy. August 6, 2009.

24.   UAMS College of Medicine, Department of Neurobiology and Developmental Sciences, Little Rock, Arkansas. Sponsor: Robert Skinner, Ph.D. Small Animal Biotelemetry for Cardiovascular Research. January 5, 2010.

25.   UAMS College of Nursing, Department of Nursing Education, Little Rock, Arkansas. Sponsor: Shannon Finley, MSN, RN. Pharmacogenomics: What Nursing Faculty Should Know. January 25, 2010.

26.   UMKC School of Pharmacy, Division of Pharmacology and Toxicology, Kansas City, Missouri. Sponsor: Anil Kumar, Ph.D. Small Animal Biotelemetry for Cardiovascular Research. November 4, 2010.

27.   Southern Illinois University, School of Pharmacy, Edwardsville. Sponsor: Mark Luer, Pharm.D. Small Animal Biotelemetry for Cardiovascular Research. February 24, 2012.

28.   UMKC School of Pharmacy, Alumni Reunion Weekend Continuing Education. Pharmacogenomics and the Future of Personalized Medicine. October 13, 2012.

29.   St. Louis College of Pharmacy. Sponsor: Wendy Duncan, Ph.D. Pharmacy Education and Health Care 1821-2021: Tradition to Revolution. November 16, 2012.

30.   UMKC School of Pharmacy, Alumni Reunion Weekend Continuing Education. The Brave New World of Lipid Lowering Treatments. October 5, 2013.

31.   UMKC Vice Provost for Faculty Affairs Faculty Development Program. Sponsor: Denis Medeiros, Ph.D. Dean Panelist for Discussion on Promotion and Tenure at UMKC. November 6, 2013.

Melchert; 09/01/16

14

32.   Wayne State University, Eugene Appelbaum College of Pharmacy and Health Sciences. Sponsor: Brian Crabtree, Pharm.D. Evolution and Revolution in Pharmacy Education. Faculty Development Workshop. January 9, 2014.

33.   Texas A&M University Health Sciences Center College of Pharmacy. Sponsor: Indra Reddy, Ph.D. Evolution and Revolution in Pharmacy Education. Faculty Development Workshop. April 3, 2014.

34.   Texas A&M University Health Sciences Center College of Pharmacy. Sponsor: Indra Reddy, Ph.D. The Best of Times for Pharmacy. Rho Chi Lecture for Student Body. April 3, 2014.

35.   American Association of Colleges of Pharmacy Pharmacy Practice Section Webinar. Developing a Scholarship Plan for Pharmacy Practice Faculty Members – How to Get Started. Panelists: V. A. Coppenrath, R. B. Melchert, M. W. Neville, and S. C. Stoner. 89 national/international participants registered. May 28, 2014.

36.   Osler Society of Greater Kansas City Fall Event. The Varieties of Alternative Medicine. Moderator: Jerald A. Burton, MD, PhD. Panelists: J.A. Drisko, R. B. Melchert, and J. L. Murray. ~60 attendees from KU Medical Center. October 22, 2014.

37.   Coordinating Board for Higher Education. Panel Discussion: Partnerships and Collaborations among Missouri Colleges and Universities. S. Graham, R. B. Melchert, H. Reid, W. Redmond, L. Brandt, and J. Lashley. Public Hearing held at the University of Missouri, Columbia. February 5, 2015.

38.   UMKC School of Pharmacy, Alumni Reunion Weekend Continuing Education. Novel Drugs and Drug Targets for Treatment of Cardiovascular Disease. October 3, 2015.

39.   American Association of Colleges of Pharmacy Interim Meeting. Debate: Con side argument to leading and managing are one in the same. G. A. Brazeau, R. Chesnut, R. B. Melchert, L. A. Ross, T. D. Sorenson, P. Piascik. Tampa, FL. February 22, 2016.

40.   UMKC Preparing Future Faculty Program Seminar for UMKC Doctoral Students. Panel Discussion: Applying and interviewing for faculty positions in diverse institutional settings. N. Donaldson, R. T. Kugler, R. B. Melchert, and M. L. Scholten. February 27, 2016.

FUNDED GRANTS (PRINCIPAL INVESTIGATOR) 1996-1997: Investigation of Astemizole- and Terfenadine-Induced Cardiotoxicity Using Primary Heart Cell Cultures University of Arkansas for Medical Sciences Medical Research Endowment Fund Research Grant Funded: $7,941-Direct Costs; 25% Time/Effort 1996-1998: Non-Sedating Antihistamine-Induced Cardiotoxicity In Vitro: Ion Channel Binding and L-Type Calcium Current American Association of Colleges of Pharmacy New Investigators Program Funded: $9,998-Direct Costs; 25% Time/Effort 1999-2001: HMG-CoA Reductase Inhibitors and Cardiac Hypertrophy Parke-Davis Research Grant Funded: $20,500-Direct Costs; $5,125-Indirect Costs; 30% Time/Effort 2000-2002: Calcium Homeostasis in the Aging Male and Female Heart National Institutes of Health, NIA Pilot Research Grant Program National Institute on Aging (1 R03 AG18989-01) Funded: $50,000-Direct Costs; $23,000-Indirect Costs; 30% Time/Effort

Melchert; 09/01/16

15

2000-2003: Fluid Resuscitation in Controlled Hemorrhagic Shock Department of Defense, Office of Naval Research (N000140010792) Funded: $362,446-Direct Costs; $149,245-Indirect Costs; 25% Time/Effort 2004-2006: Altering Myoblasts to Enhance Cardiac Implantation National Institutes of Health, National Heart Lung and Blood Institute (1 R21 HL072136-01). Named PI in June, 2004 (former PI Richard H. Kennedy). Funded: $150,000-Direct Costs; $63,000-Indirect Costs; 20% Time/Effort 2009: Visual Sonics Imaging Equipment Grant (High-Resolution, Small Animal Ultrasound) Arkansas Tobacco Settlement Funds. Funded: $300,000-Direct Costs FUNDED GRANTS (CO-INVESTIGATOR) 1997-1998: Effects of Interleukin-6 on Hepatic Metabolism of the Triazole Itraconazole. Principal Investigator: Paul O. Gubbins, Pharm.D., UAMS College of Pharmacy Society of Infectious Disease Pharmacists; $20,000-Direct Costs; 5% Time/Effort 1997-1998: Effect of Nutritional Alteration on the Activity of CYP3A Subfamily in Primary Rat Hepatocytes Principal Investigator: Cindy D. Stowe, Pharm.D., UAMS College of Pharmacy UAMS Medical Research Endowment Fund; $7,873-Direct Costs; 5% Time/Effort 1998-1999: Gender and Glutathione on Doxorubicin Cardiotoxicity Principal Investigator: Richard H. Kennedy, Ph.D., UAMS College of Pharmacy Arkansas Breast Cancer Research Program; $35,000-Direct Costs; 10% Time/Effort 1998-1999: Acute Phase Response and BBB P-gp Function Principal Investigator: Mark S. Luer, Pharm.D., UAMS College of Pharmacy UAMS Medical Research Endowment Fund; $14,998-Direct Costs; 5% Time/Effort 1999-2000: Drug-Cytokine Interaction: IL-6 Impact on BBB Transport Principal Investigator: Mark S. Luer, Pharm.D., UAMS College of Pharmacy American College of Clinical Pharmacy; $9,975-Direct Costs; 5% Time/Effort 2001-2003: Effects of Gender on Cardiac Aging Principal Investigator: Richard H. Kennedy, Ph.D., UAMS College of Pharmacy American Heart Association, Heartland Affiliate Grant-in-Aid; $100,000-Direct Costs; 5% Time/Effort 2002-2004: Time Dependent Changes in Cellular Environment Determine the Functional Outcome of Cellular Cardiomyoplasty Principal Investigator: Esther E. Dupont-Versteegden, Ph.D., UAMS College of Medicine, Department of Geriatrics; American Heart Association, Heartland Affiliate Beginning Grant-in-Aid; $121,000-Direct Costs; 25% Time/Effort 2002-2004: Altering Myoblasts to Enhance Cardiac Implantation Principal Investigator: Richard H. Kennedy, Ph.D., UAMS College of Pharmacy National Institutes of Health, National Heart Lung and Blood Institute (1 R21 HL072136-01). Changed PI to Dr. Melchert in June, 2004; $300,000-Direct Costs; $144,000-Indirect Costs; 15% Time/Effort 2009-2012: Vascular Calcium Channel Expression in Hypertension. Principal Investigator: Nancy J. Rusch, Ph.D., UAMS College of Medicine, Department of Pharmacology and Toxicology; National Institutes of Health Competitive Renewal Submission (2 R01 HL064806-09A1); 0.8 Percentile $1,000,000-Direct Costs; $439,151-Indirect Costs; 10% Time/Effort

Melchert; 09/01/16

16

2009-2013: Long-term Antihypertensive Therapy by Delivery of the BK Channel Gene to VSMCs. Principal Investigator: Nancy J. Rusch, Ph.D., UAMS College of Medicine, Department of Pharmacology and Toxicology; National Institutes of Health R01 HL 0932526-01; 12.7 Percentile $1,000,000-Direct Costs; $450,000-Indirect Costs; 10% Time/Effort 2009-2013: MicroRNA to decrease vascular CaV1.2 in hypertension Principal Investigator: Philip Palade, Ph.D. and Li Pang, Ph.D., UAMS College of Medicine, Department of Pharmacology and Toxicology; National Institutes of Health R01 HL095846; $1,250,000-Direct Costs; $562,500-Indirect Costs; 5% Time/Effort PUBLICATIONS 1.   R.B. Melchert, J.A. Eselin, J.F. O'Dell, and A.A. Welder. Effects of nitrendipine on cocaine-

induced toxicity evaluated in primary myocardial cell cultures. J. Pharm. Sci. 80:700-704, 1991. 2.   A.A. Welder, J.F. O'Dell, R.B. Melchert, and J.A. Eselin. Evaluation of the combined toxic

effects of cocaine and alcohol on primary myocardial cell cultures. Toxicol. In Vitro. 5:247-255, 1991.

3.   A.A. Welder, J.A. Eselin, R.B. Melchert, S.K. Davis, and J.F. O'Dell. The effects of cocaine and norepinephrine on primary cultures of neonatal rat myocardial cells. J. Toxicol. Environ. Health. 36:75-90, 1992.

4.   R.B. Melchert, T.J. Herron, and A.A. Welder. The effect of anabolic-androgenic steroids on primary myocardial cell cultures. Med. Sci. Sports Exerc. 24:206-212, 1992.

5.   A.A. Welder and R.B. Melchert. Evaluation of the combined effects of cocaine and morphine on postnatal rat heart cell cultures. Res. Commun. Sub. Abuse. 13:45-60, 1992.

6.   R.B. Melchert and A.A. Welder. The combined effects of cocaine and amphetamine in primary myocardial cell cultures. Reprod. Toxicol. 6:467-473, 1992.

7.   R.B. Melchert, C. Göldlin, U. Zweifel, A.A. Welder, and U.A. Boelsterli. Differential toxicity of cocaine and its isomers, (+)-cocaine and (-)-Y-cocaine, is associated with stereoselective hydrolysis by hepatic carboxylesterases in cultured rat hepatocytes. Chem.-Biol. Interact. 84:243-258, 1992.

8.   A.A. Welder, P. Grammas, R.D. Fugate, K. Rohrer, and R.B. Melchert. A primary culture system of rat heart-derived endothelial cells for evaluating cocaine-induced vascular injury. Toxicol. Meth. 3:109-118, 1993.

9.   A.A. Welder, L.J. Dickson, and R.B. Melchert. Cocaethylene toxicity in rat primary myocardial cell cultures. Alcohol. 10:285-290, 1993.

10.   A.A. Welder and R.B. Melchert. Cardiotoxic effects of cocaine and anabolic-androgenic steroids in the athlete. (Review). J. Pharmacol. Toxicol. Meth. 29:61-68, 1993.

11.   A.A. Welder, P. Grammas, and R.B. Melchert. Cellular mechanisms of cocaine cardiotoxicity. (Review). Toxicol. Lett. 69:227-238, 1993.

12.   A.A. Welder, J.W. Robertson, and R.B. Melchert. Toxic effects of anabolic-androgenic steroids in primary rat hepatic cell cultures. J. Pharm. Toxicol. Meth. 33:187-195, 1995.

13.   A.A. Welder, J.W. Robertson, R.D. Fugate, and R.B. Melchert. Anabolic-androgenic steroid-induced toxicity in primary neonatal rat myocardial cell cultures. Toxicol. Appl. Pharmacol. 133:328-342, 1995.

14.   R.B. Melchert and A.A. Welder. Cardiovascular effects of androgenic-anabolic steroids. (Review). Med. Sci. Sports Exer. 27:1252-1262, 1995.

Melchert; 09/01/16

17

15.   R.B. Melchert, P.S. Levin, and D. Acosta. Cardiotoxicity of non-sedating antihistamines in vitro. In Vitro Toxicol. 9:431-440, 1996.

16.   S. Liu, R.B. Melchert, and R.H. Kennedy. Inhibition of L-type Ca++ channel current in rat ventricular myocytes by terfenadine. Circ. Res. 81(2):202-210, 1997.

17.   J. Davila, R.J. Rodriguez, R.B. Melchert, and D. Acosta. Predictive value of in vitro model systems in toxicology. (Review). Ann. Rev. Pharmacol. Toxicol. 38:63-96, 1998.

18.   S.J. Liu, R.P. Wyeth, R.B. Melchert, and R.H. Kennedy. Aging-associated changes in whole cell K+ and L-type Ca2+ currents in rat ventricular myocytes. Am. J. Physiol. Heart Circ. Physiol. 279:H889-H900, 2000.

19.   R.B. Melchert, C. Yuan, and D. Acosta. Introduction to Cardiotoxicity. In: Target Organ Toxicology Series: Cardiovascular Toxicology, Third Edition. D. Acosta, Ed. Taylor & Francis, Washington, DC. pp. 3-30, 2001.

20.   R.B. Melchert, R.H. Kennedy, and D. Acosta. Cardiovascular Effects of Steroidal Compounds. In: Target Organ Toxicology Series: Cardiovascular Toxicology, Third Edition. D. Acosta, Ed. Taylor & Francis, Washington, DC. pp. 425-475, 2001.

21.   K.S. Ramos, R.B. Melchert, E. Chacon, and D. Acosta. Toxic Responses of the Heart and Vascular System. In: Casarett and Doull’s Toxicology The Basic Science of Poisons, Sixth Edition. C. D. Klaassen, Ed. McGraw-Hill, New York. pp. 597-651, 2001.

22.   R.B. Melchert, H. Liu, M.C. Granberry, and R.H. Kennedy. Lovastatin inhibits phenylephrine-induced ERK activation and growth of cardiac myocytes. Cardiovasc. Toxicol. 1:237-252, 2001.

23.   L.A. Mitchell, D.F. Grant, R.B. Melchert, N.M. Petty, and R.H. Kennedy. Linoleic acid metabolites act acutely as positive inotropic agents in isolated rat heart. Cardiovasc. Toxicol. 2:219-229, 2002.

24.   R.B. Melchert, J. Joseph, and R.H. Kennedy. Interaction of xenobiotics with myocardial signal transduction pathways. (Review). Cardiovasc. Toxicol. 2:1-23, 2002.

25.   K.S. Ramos, R.B. Melchert, E. Chacon, and D. Acosta. Toxic Responses of the Heart and Vascular System. In: Casarett and Doull’s Essentials of Toxicology. C. D. Klaassen and J. B. Watkins, Eds. McGraw-Hill, New York. pp. 266-287, 2003.

26.   J. Joseph, L. Joseph, N.S. Shekhawat, S. Devi, J. Wang, R.B. Melchert, M. Hauer-Jensen, and R. H. Kennedy. Hyperhomocysteinemia leads to pathologic ventricular hypertrophy in normotensive rats. Am. J. Physiol. Heart Circ. Physiol. 285(2):H679-H686, 2003.

27.   P.O. Gubbins, R.B. Melchert, S.A. McConnell, A.H. Franks, S.R. Penzak, and B.J. Gurley. Effect of interleukin 6 on the hepatic metabolism of itraconazole and its metabolite hydroxyitraconazole using primary human hepatocytes. Pharmacology. 67:195-201, 2003.

28.   M.E. Maris, R.B. Melchert, J. Joseph, and R.H. Kennedy. Gender differences in blood pressure and heart rate in spontaneous hypertensive and Wistar-Kyoto rats. Clin. Exp. Pharmacol. Physiol. 32:35-39, 2005.

29.   R.H. Kennedy, R.B. Melchert, and J. Joseph. Cardiovascular effects of hyperhomocysteinemia in conscious unrestrained rats. Am. J. Hypertension. 19:94-97, 2006.

30.   S. Devi, R.H. Kennedy, L. Joseph, N.S. Shekhawat, R.B. Melchert, and J. Joseph. Effect of long-term hyperhomocysteinemia on myocardial structure and function in hypertensive rats. Cardiovasc. Pathol. 15(2):75-82, 2006.

31.   R.H. Kennedy, R. Owings, J. Joseph, R.B. Melchert, M. Hauer-Jensen, and M. Boerma. Acute dilatory and negative inotropic effects of homocysteine are inhibited by an adenosine blocker. Clin. Exp. Pharmacol. Physiol. 33(4):340-344, 2006.

Melchert; 09/01/16

18

32.   S. Ghosh, D. Hill, N. M. Petty, R.B. Melchert, B. Luo, D.F. Grant, and D.K. Dey. Statistical approach to metabonomic analysis of rat urine following surgical trauma. J. Chemometrics. 20(3-4):87-98, 2006.

33.   R.B. Melchert, S.M. Belcher, and R.H. Kennedy. Cardiovascular Effects of Steroidal Compounds. In: Target Organ Toxicology Series: Cardiovascular Toxicology, Fourth Edition. D. Acosta, Ed. Informa Healthcare, New York. pp. 367-428, 2008.

34.   D.F. Thompson, K.C. Farmer, D.G. Beall, D.J. Evans, R.B. Melchert, L.A. Ross, and B.J. Schmoll. Identifying perceptions of professionalism in pharmacy using a four frame leadership model?. Am. J. Pharm. Ed. 72(4):90-98, 2008.

35.   B.Y. Kang, Y. You, S. Bandyopadhyay, N. Agrawal, R.B. Melchert, A.G. Basnakian, Y. Liu, and P.L. Hermonat. Cervical cancer isolate PT3, super-permissive for adeno-associated virus replication, over-expresses DNA polymerase d, PCNA, RFC and RPA. BMC Microbiol. 9:79, 2009.

36.   S.J. Liu and R.B. Melchert. Primary Culture of Cardiomyocytes – In Vitro Model for Evaluating Cardiotoxicity. In: Comprehensive Toxicology, Second Edition. Elsevier, pp. 113-131, 2010.

37.   L. Cui, D. Pierce, K.E. Light, R.B. Melchert, Q. Fu, K.S. Kumar, and M. Hauer-Jensen. Sublethal total body irradiation leads to early cerebellar damage and oxidative stress. Curr. Neurovasc. Res. 7:125-135, 2010.

38.   R.B. Melchert and J.E. Fincham. Escalating medication shortages: a public health and patient care crisis. Missouri Medicine. January/February, 2012.

39.   M.S. Medina, A.S. Bouldin, M. Gonyeau, J.C. Kissack, W.T. Maldonado, R.B. Melchert, O. Moukhachen, and C.M. Plaza. Report of the 2011-2012 Academic Affairs Standing Committee: The evolving role of scholarly teaching in teaching excellence for current and future faculty. Am. J. Pharm. Ed. 76(6):Article S6, 2012.

40.   M.S. Medina, C.M. Plaza, C.D. Stowe, E.T. Robinson, G. DeLander, D.E. Beck, R.B. Melchert, R.B. Supernaw, V.F. Roche, B.L. Gleason, M.N. Strong, A. Bain, G.E. Meyer, B.J. Dong, J. Rochon, and P. Johnston. Center for the Advancement of Pharmacy Education 2013 Educational Outcomes. Am. J. Pharm. Ed. 77(8):Article 162, 2013.

41.   M.S. Medina, C.M. Plaza, C.D. Stowe, E. T. Robinson, G. DeLander, D.E. Beck, R.B. Melchert, R.B. Supernaw, V.F. Roche, B.L. Gleason, M.N. Strong, A. Bain, G.E. Meyer, B.J. Dong, J. Rochon, and P. Johnston. Report of the 2012-2013 Academic Affairs Standing Committee: Revising the Center for the Advancement of Pharmacy Education (CAPE) Educational Outcomes 2013. Am. J. Pharm. Ed. 77(8):Article S8, 2013.

42.   R.B. Melchert. Chapter 15. Partners on the Hill. In: A Proven Experiment. Looking Back at the UMKC School of Medicine. J. A. Burton and P. G. Buron, Eds. Rockhill Books, Kansas City. pp. 204-206, 2014.

43.   K. Hardinger, L. Garavalia, M.R. Graham, P. A. Marken, R.B. Melchert, L.A. Nelson, and A. Stahnke. Enrollment management strategies in the professional pharmacy program: a focus on progression and retention. Currents in Pharmacy Teaching and Learning. 7(2):199-206, 2015.

44.   B. Oh, R.B. Melchert, and C.H. Lee. Bio-inspired robust hydrogel for the delivery of mesenchymal stem cells. Pharm. Res. 32(10):3213-3227, 2015.

45.   S.J. Liu and R.B. Melchert. Primary Culture of Cardiomyocytes – In Vitro Model for Evaluating Cardiotoxicity. In: Comprehensive Toxicology, Third Edition. Elsevier (In Press).

Melchert; 09/01/16

19

ABSTRACTS AND NATIONAL/REGIONAL MEETING PRESENTATIONS 1.   R.B. Melchert, J.A. Eselin, J.F. O'Dell, and A.A. Welder. Combined effects of cocaine and

nitrendipine on primary myocardial cell cultures. The Toxicologist. 10:33, 1990. 2.   J.F. O'Dell, R.B. Melchert, J.A. Eselin, and A.A. Welder. Toxic effects of cocaine and alcohol

evaluated in primary myocardial cell cultures. The Toxicologist. 10:33, 1990. 3.   J.A. Eselin, J.F. O'Dell, R.B. Melchert, and A.A. Welder. Effects of cocaine and

norepinephrine on primary myocardial cell cultures. The Toxicologist. 10:34, 1990. 4.   R.B. Melchert, T.J. Herron, S.K. Davis, and A.A. Welder. The cardiotoxic effects of anabolic-

androgenic steroids on primary neonatal cell cultures. The Toxicologist. 11:339, 1991. 5.   S.K. Davis, R.B. Melchert, and A.A. Welder. Cardiotoxicity of cocaine in adult cell cultures. In

Vitro Cell. Devel. Biol. 27:154A, 1991. 6.   R.B. Melchert, S.K. Davis, and A.A. Welder. Cardiotoxicity of cocaine and amphetamine in

neonatal cell cultures. In Vitro Cell. Devel. Biol. 27:155A, 1991. 7.   M.L. Kaiser, T.J. Herron, R.B. Melchert, and A.A. Welder. The effects of the cocaine

metabolite benzoylecgonine and a cocaine analog (-)-3-(4-Fluoro-phenyl) tropan-2-carboxylic acid methyl ester tartrate on postnatal primary rat myocardial cell cultures. The Toxicologist. 12:381, 1992.

8.   T.J. Herron, M.L. Kaiser, R.B. Melchert, and A.A. Welder. The effects of cocaine and hypoxia on postnatal primary rat myocardial cell cultures. The Toxicologist. 12:381, 1992.

9.   C. Göldlin, R.B. Melchert, U. Zweifel, A.A. Welder, and U.A. Boelsterli. Differential toxicity of cocaine and its isomers (+)-cocaine and (-)-pseudococaine is associated with different rates of P-450-mediated bioactivation and hydrolytic inactivation in cultured rat hepatocytes. The Toxicologist. 12:66, 1992.

10.   R.B. Melchert, T.J. Herron, and A.A. Welder. Testosterone-induced ultrastructural changes in primary neonatal rat myocardial cell cultures. In Vitro Cell. Devel. Biol. 28:136A, 1992.

11.   J.W. Robertson, M.A. Stowers, R.B. Melchert, and A.A. Welder. The toxic effects of anabolic-androgenic steroids on primary rat hepatic cell cultures. The Toxicologist. 13:200,1993.

12.   K. Dinh, R.B. Melchert, and A.A. Welder. The effects of progesterone on cocaine- induced toxicity in primary neonatal rat myocardial cell cutlures. The Toxicologist. 13:307,1993.

13.   G.R. Gazda, S.M. Dusenbery, R.B. Melchert, and A.A. Welder. Toxic effects of an anabolic-androgenic steroid and cocaine on primary heart cell cultures. The Toxicologist. 13:307,1993.

14.   A.A. Welder, P. Grammas, R. Fugate, T. Herron, K. Rohrer, and R.B. Melchert. A primary culture system of rat heart derived endothelial cells for evaluating cocaine-induced vascular injury. The Toxicologist. 13:308,1993.

15.   L.J. Dickson, A.A. Welder, and R.B. Melchert. Toxic effects of cocaethylene in primary neonatal rat myocardial cell cultures. The Toxicologist. 13:308,1993.

16.   R.B. Melchert, J.W. Robertson, M.A. Stowers, and A.A. Welder. A primary culture system of rat liver cell cultures for the evaluation of "stacking" anabolic-androgenic steroids. The Toxicologist. 13:310,1993.

17.   K. Dinh, R.B. Melchert, M. Lambros, and A.A. Welder. Cocaine metabolism in primary neonatal rat myocardial cell cultures. The Toxicologist. 14:375, 1994.

18.   J.W. Robertson, R.B. Melchert, and A.A. Welder. GSH levels in primary rat hepatic cell cultures exposed to 17 a-alkylated anabolic-androgenic steroids. The Toxicologist. 14:190, 1994.

19.   R.B. Melchert, J.W. Robertson, R.D. Fugate, and A.A. Welder. Anabolic-androgenic steroid-induced toxicity in primary neonatal rat myocardial cell cultures. The Toxicologist. 14:375, 1994.

Melchert; 09/01/16

20

20.   A. Rastogi, J.W. Robertson, R.B. Melchert, and A.A. Welder. The combined effects of anabolic-androgenic steroids and cocaine on primary myocardial cell cultures. The Toxicologist. 15:129, 1995.

21.   R.B. Melchert, P. Levin, and D. Acosta. Tertiary-butyl hydroperoxide toxicity as a model of oxidative stress in primary neonatal rat keratinocyte cultures. The Toxicologist. 15:320, 1995.

22.   R.B. Melchert, P. Levin, and D. Acosta. Terfenadine and astemizole, but not quinidine, induce toxicity in primary neonatal rat myocardial cell cultures. FASEB J. 9:A934, 1995.

23.   P.S. Levin, R.B. Melchert, and D. Acosta. Catecholamines and ventricular myocytes: an in vitro model for studying the cardiotoxicity of cocaine. Fund. Appl. Toxicol. 30:125, 1996.

24.   G.M. Curtin, R.B. Melchert, and D. Acosta. Oxidant-induced cellular senescence. Fund. Appl. Toxicol. 30:134, 1996.

25.   A.M. Harden and R.B. Melchert. The effects of nonsedating antihistamines on contractile activity of heart cells in vitro. The National McNair Journal. 4:41, 1996.

26.   R.B. Melchert, H. Wang, and L.G. Jones. Cardiac hypertrophic stimulation by anabolic-androgenic steroids: putative role for ERK, JNK, and PKC signaling pathways. American Association of Pharmaceutical Scientists, Southern Regional Discussion Group, First Annual Meeting. The University of Mississippi. 1998.

27.   S.J. Liu, R.P. Wyeth, R.B. Melchert, and R.H. Kennedy. Aging-associated changes in K and Ca currents in rat ventricular myocytes. Journal of Cellular and Molecular Cardiology. 31:A44, 1999.

28.   R.B. Melchert, H. Wang, and L.G. Jones. Cardiac hypertrophic stimulation by anabolic-androgenic steroids: putative role for ERK, JNK, and PKC signaling pathways. FASEB Summer Conference: Steroid Receptors in the Plasma Membrane. Copper Mountain, Colorado. 1999.

29.   C.D. Stowe, R.B. Melchert, and L.P. James. Effect of dietary protein on CYP3A activity in primary rat hepatocyte culture. Clinical Pharmacology & Therapeutics. 67(2):149, 2000.

30.   A.H. Franks, R.B. Melchert, P.O. Gubbins. The effect of interleukin-6 on hepatic metabolism of the triazole antifungal itraconazole in primary rat hepatocytes. Am. J. Pharm. Ed. 64(suppl 1):122S, 2000.

31.   P.O. Gubbins, R.B. Melchert, S.A. McConnell, A.H. Franks, S.R. Penzak, and B.J. Gurley. The effect of interleukin-6 on the hepatic metabolism of itraconazole and its metabolite hydroxyitraconazole. Pharmacotherapy. 20:1263, 2001.

32.   R.B. Melchert, H. Liu, M.C. Granberry, and R.H. Kennedy. Lovastatin inhibits phenylephrine-induced ERK activation and growth of cardiac myocytes. The Toxicologist. 60:12-13, 2001.

33.   R.B. Melchert, R. Klima, N.M. Petty, B.L. McNew, M.S. Luer, and R.H. Kennedy. Survival and cardiovascular function in conscious rats subjected to controlled hemorrhagic shock and fluid resuscitation. Presented at the Combat Fluid Resuscitation 2001 meeting in Bethesda, MD, June 18-20, 2001.

34.   D.J. Cao, S.J. Liu, R.B. Melchert, and R.H. Kennedy. Gender-related differences in the contractile function of ventricular myocytes during aging. FASEB J. 16:A392, 2002.

35.   N.M. Petty, B.L. McNew, R.H. Kennedy, and R.B. Melchert. Sodium/hydrogen exchange inhibitors for resuscitation of hemorrhagic shock. American Association of Pharmaceutical Scientists, Southern Regional Discussion Group. The University of Arkansas for Medical Sciences, Little Rock, AR, May 30-31, 2002.

36.   B.L. McNew, N.M. Petty, and R.B. Melchert. Atorvastatin inhibits phenylephrine-induced growth of cardiac myocytes. American Association of Pharmaceutical Scientists, Southern

Melchert; 09/01/16

21

Regional Discussion Group. The University of Arkansas for Medical Sciences, Little Rock, AR, May 30-31, 2002.

37.   B.J. Gurley, R.B. Melchert, N.M. Petty, S. Gardner, L. Lamps, and M. Hubbard. Drugs disguised as supplements: the ephedra controversy. American Academy of Forensic Sciences Meeting. February 17, 2004.

38.   A. Mangu, N. Shekhawat, J. Joseph, and R.B. Melchert. Lovastatin inhibits cardiac fibroblast proliferation. American Association of Pharmaceutical Scientists, Southern Regional Discussion Group. The University of Tennessee Health Science Center, Memphis, TN. May 17-18, 2004.

39.   N.S. Shekhawat, J. Joseph, R.B. Melchert, S. Devi, A. Mangu, and R.H. Kennedy. Effects of homocysteine on adult rat cardiac fibroblasts and cardiac myocytes. American Association of Pharmaceutical Scientists, Southern Regional Discussion Group. The University of Tennessee Health Science Center, Memphis, TN May 17-18, 2004.

40.   D. Beall, D.J. Evans, K.C. Farmer, R.B. Melchert, L.A. Ross, B.J. Schmoll, and D.F. Thompson. Is professionalism in pharmacy education addressed from a four frame leadership model? American Association of Colleges of Pharmacy Annual Meeting. San Diego, CA. July 8-13, 2006.

41.   S.W. Rhee, K. Thakali, R.B. Melchert, L. Pang, T.W. Fletcher, K.A. Roberto, P.L. Hermonat, and N.J. Rusch. AAV delivery of the BK channel gene to vascular smooth muscle as a long-lasting antihypertensive strategy. Biophys. J 94:3029, 2008.

42.   B.Y. Kang, H. You, S. Bandyopadhyay, N. Agrawal, R.B. Melchert, A. G. Basnakian, Y. Liu, and P. L. Hermonat. Cervical cancer isolate PT3, super-permissive for adeno-associated virus replication, over-expresses DNA polymerase delta, PCNA, RFC, and RPA. XII Parvovirus Workshop 2008, Cordoba, Spain.

43.   L. Pang, S. Sonkusare, K. Thakali, R. Melchert, K. Roberto, and P. Palade. AAV-mediated vascular smooth muscle-specific knockdown of Cav1.2 as a long-term anti-hypertensive therapy. FASEB J. 23: 932.4, 2009.

44.   L. Garavalia, R.B. Melchert, M.R. Graham, P.A. Marken, L.A. Nelson, A.M. Stankhe, K.L. Hardinger. Academic progression: defining failure in professional pharmacy programs. American Association of Colleges of Pharmacy Annual Meeting. Chicago, IL July 12-17, 2013.

45.   P.A. Marken, M.R. Graham, K.L. Hardinger, S.M. Janasz, L.A. Nelson, and R.B. Melchert. Addressing retention challenges-one school’s experience with a student success program. American Association of Colleges of Pharmacy Annual Meeting. Anaheim, CA July 23-27, 2016.

46.   R.B. Melchert. Deans Networking Session III: Fostering an Entrepreneurial Spirit in Schools of Pharmacy. American Association of Colleges of Pharmacy Annual Meeting. Anaheim, CA July 23-27, 2016.